Immatics Financials
| IMTX Stock | USD 7.18 0.09 1.24% |
Immatics |
Understanding current and past Immatics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immatics' financial statements are interrelated, with each one affecting the others. For example, an increase in Immatics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Immatics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immatics NV. Check Immatics' Beneish M Score to see the likelihood of Immatics' management manipulating its earnings.
Immatics Stock Summary
Immatics competes with Crinetics Pharmaceuticals, Alx Oncology, Bioatla, Aerovate Therapeutics, and Keros Therapeutics. Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | NL0015285941 |
| CUSIP | N44445109 G3165V109 G3165V117 |
| Location | Germany |
| Business Address | Paul-Ehrlich-Strasse 15, Tbingen, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.immatics.com |
| Phone | 49 7071 5397 0 |
| Currency | USD - US Dollar |
Immatics Key Financial Ratios
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Target Price | 16.75 | ||||
| Number Of Employees | 542 | ||||
| Beta | 0.78 |
Immatics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immatics's current stock value. Our valuation model uses many indicators to compare Immatics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immatics competition to find correlations between indicators driving Immatics's intrinsic value. More Info.Immatics NV is rated third overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immatics' earnings, one of the primary drivers of an investment's value.Immatics NV Systematic Risk
Immatics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immatics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Immatics NV correlated with the market. If Beta is less than 0 Immatics generally moves in the opposite direction as compared to the market. If Immatics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immatics NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immatics is generally in the same direction as the market. If Beta > 1 Immatics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Immatics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Immatics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Immatics' financials are consistent with your investment objective using the following steps:- Review Immatics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Immatics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Immatics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Immatics' stock is overvalued or undervalued.
Immatics December 17, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Immatics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immatics NV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immatics NV based on widely used predictive technical indicators. In general, we focus on analyzing Immatics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immatics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.29) | |||
| Maximum Drawdown | 20.47 | |||
| Value At Risk | (4.28) | |||
| Potential Upside | 2.77 |
Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.